The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.

Including the name of the #1 company to buy.

Kanya Rajangam Biography and Net Worth

Insider of Nkarta

Dr. Rajangam joined Nkarta as Senior Vice President and Chief Medical Officer in 2018 to lead all clinical development activities. Dr. Rajangam most recently served as Chief Medical Officer at Atara Biotherapeutics where she was responsible for the development of allogeneic and autologous T-cell therapies for oncology, neurology and infectious disease. Prior to Atara, she was Chief Medical Officer of Cleave Biosciences, where she led clinical development of the company’s oncology pipeline. Dr. Rajangam also served in roles with increasing responsibilities at Onyx and Exelixis, during which time she contributed to various stages of development and/or approval of multiple oncology drugs including Kyprolis®, Cotellic® and Cometriq®/Cabometyx®. Dr. Rajangam, a general surgeon, received a medical degree from St. Johns’ Medical College in India. She also received a PhD in biomedical cell and tissue engineering from Northwestern University, Evanston, IL.

How do I contact Kanya Rajangam?: The corporate mailing address for Dr. Rajangam and other Nkarta executives is 6000 SHORELINE COURT SUITE 102, SOUTH SAN FRANCISCO CA, 94080. Nkarta can also be reached via phone at 925-407-1049 and via email at [email protected]. Learn More on Kanya Rajangam's contact information.
Has Kanya Rajangam been buying or selling shares of Nkarta?: Kanya Rajangam has not been actively trading shares of Nkarta during the last quarter. Most recently, Kanya Rajangam sold 10,000 shares of the business's stock in a transaction on Thursday, August 5th. The shares were sold at an average price of $37.28, for a transaction totalling $372,800.00. Learn More on Kanya Rajangam's trading history.
Who are Nkarta's active insiders?: Nkarta's insider roster includes Ralph Brandenberger (Insider), Paul Hastings (CEO), Nadir Mahmood (Insider), and Kanya Rajangam (Insider). Learn More on Nkarta's active insiders.
Are insiders buying or selling shares of Nkarta?: During the last year, Nkarta insiders bought shares 1 times. They purchased a total of 2,000,000 shares worth more than $20,000,000.00. During the last year, insiders at the sold shares 4 times. They sold a total of 20,788 shares worth more than $192,680.26. The most recent insider tranaction occured on July, 16th when insider Alicia J Hager sold 3,396 shares worth more than $27,168.00. Insiders at Nkarta own 8.7% of the company. Learn More about insider trades at Nkarta.
Information on this page was last updated on 7/16/2024.

Kanya Rajangam Insider Trading History at Nkarta

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/5/2021	Sell	10,000	$37.28	$372,800.00

Kanya Rajangam Buying and Selling Activity at Nkarta

Nkarta Company Overview

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Today's Range

Now: $2.45

$2.40

$2.50

50 Day Range

MA: $3.79

$2.44

$5.65

2 Week Range

Now: $2.45

$2.38

$16.24

Volume

1,936,972 shs

Average Volume

1,120,529 shs

Market Capitalization

$172.90 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86

Financial Prophecy

From Porter & Company | Ad